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Abstract
Background: Umbilical cord banks are a central component, as umbilical cord tissue providers,
in both medical treatment and scientific research with stem cells. But, whereas the creation of
umbilical cord banks is seen as successful practice, it is perceived as a risky style of play by others.
This article examines and discusses the ethical, medical and legal considerations that arise from the
operation of umbilical cord banks in Mexico.
Discussion: A number of experts have stated that the use of umbilical cord goes beyond the mere
utilization of human tissues for the purpose of treatment. This tissue is also used in research
studies: genetic studies, studies to evaluate the effectiveness of new antibiotics, studies to identify
new proteins, etc. Meanwhile, others claim that the law and other norms for the functioning of cord
banks are not consistent and are poorly defined. Some of these critics point out that the
confidentiality of donor information is handled differently in different places. The fact that private
cord banks offer their services as "biological insurance" in order to obtain informed consent by
promising the parents that the tissue that will be stored insures the health of their child in the
future raises the issue of whether the consent is freely given or given under coercion. Another
consideration that must be made in relation to privately owned cord banks has to do with the
ownership of the stored umbilical cord.
Summary: Conflicts between moral principles and economic interests (non-moral principles)
cause dilemmas in the clinical practice of umbilical cord blood storage and use especially in privately
owned banks. This article presents a reflection and some of the guidelines that must be followed
by umbilical cord banks in order to deal with these conflicts. This reflection is based on the
fundamental notions of ethics and public health and seeks to be a contribution towards the
improvement of umbilical cord banks' performance.
Background
The extraordinary scientific and technological advance of
contemporary medicine constantly leads toward the
introduction of new treatments, as well as treatments for
illnesses that were previously untreatable; one example of
this is the discovery and introduction into clinical medi-
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cine of the use of umbilical cord blood for the acquisition
and transplantation of stem cells to treat bone marrow
disorders, both genetic and acquired [1-3]. Similarly, the
hypothesis that these cells have enormous therapeutic
possibilities in different illnesses is being actively
researched. These illnesses affect the following body sys-
tems: cardiovascular, neurological, gastrointestinal, bone
and joint, endocrine and skin. The acquisition of stem
cells from umbilical cord blood for the treatment of these
illnesses brings with it the obligation to create and operate
umbilical cord banks (UCB) in a manner that is congruent
with the ethics of clinical health care and public health
[4].
When they are classified by the source of their funding,
UCBs may be publicly funded or funded for profit. Pub-
licly funded banks, as created by the government, pro-
mote the altruistic donation; and, even though these
banks store umbilical cord tissue in order to use it to ben-
efit any person who may need it, they also store samples
of the donated tissue for autologous transplant in certain
selected cases. In contrast, for profit banks, created with
private capital, require that the cost of the service be paid
by the donors, and the donated tissue is meant for autol-
ogous use and not for transplants to others, although
occasionally this may happen [1,3].
These umbilical cord banks first appeared in the world in
the 1980s. At present there are approximately 107 of them
worldwide and the majority is publicly owned. Official
data on these banks reveals that by the year 2007 the
number of samples stored was 406,000; the number of
allogenic transplants was 2,743; 79% of the cord blood
units were used for single or double transplantation [5].
These data also reveal that there is a minimal autologous
utilization of the tissue stored, which is estimated to be 1
in 20,000 samples stored during the first 20 years of life of
the donor [6]. These data support the projections of Bal-
len who estimates that the probability of using one's own
cord blood varies between 1:2500 (0.04%) and 1:200,000
(0.0005%) in the first 20 years of life [7,8]. It is interesting
to note that in almost every case in the United States
where a family was caught by surprise by a deadly disease
and a transplant was needed, a cord blood match was
found at a public blood bank, such as those at Georget-
own University Medical Center, the New York Blood
Center, UCLA or Duke University [9]. In the United King-
dom, a bank sized of 50,000 could ensure at least one
donor unit available for 80–98% of the population [10].
In Mexico there are three public banks: "CordMx" which
belongs to the National Center for Blood Transfusion of
the Federal Department of Health, the Bank of the Univer-
sity Hospital of Nuevo Leon, and the Central Blood Bank
of the "La Raza" National Medical Centre which is part of
the Mexican Institute of Social Security [11]. CordMx is
the only Latin American bank to be registered with Net-
cord, an international foundation which affiliates umbili-
cal cord blood banks [12]. CordMx belongs to the World
Marrow Donor Association (WMDA). On the basis of the
percentage of cord blood units (CB) provided for trans-
plantation in relation to the number of CB units present,
in 2007, CordMx was first in the worldwide list of banks.
The utilization rate was 3.79%. Furthermore, as regards to
the percentage of CB units exported, this public bank was
thirteenth in that list [5].
Mexico is in fourth place worldwide in the number of pri-
vate banks it has; it is estimated that there are at least one
dozen of them [13]. Private banks actually cover more
geographical areas than public banks. Since more than
half of the population of the country cannot afford the
services of private banks, and Mexico has not yet enacted
specific legislation to regulate them, there are issues about
the ethics of their operation. The table 1 summarizes
some of the differences in the operation of Umbilical
Cord Blood Banks in Mexico.
Up to June 2009, the umbilical cord blood bank at the "La
Raza" National Medical Centre reported 500 tissue sam-
ples in storage, and to have performed 37 transplants; this
number represents an utilization rate of 7.4% of the tissue
stored. In order to guarantee the quality of the stored tis-
sue, this UCB does a follow up of all tissues and donors
during a three to six month period [Guerra-Marquez A.
Unpublished observations].
Research has shown that the HLA (Human Leukocyte
Antigen) compatibility of a transplant is smaller in allo-
genic transplants than in autologous transplants; never-
theless, the storage capacity of public banks promotes
availability and genetic diversity [7,10,14,15]. Table 2
summarizes some of the major therapeutic indications for
the transplant of haematopoietic stem cells approved by
the Ministry of Health in Mexico [16]. But, the American
Academy of Pediatrics and American Society of Haematol-
ogy extend the list of therapeutic indications to other dis-
orders such as: malignancies, bone marrow failfure,
hemoglobinopathies, inmunofeficiencies, and inborn
errors of metabolism [15,17-20]. The Iberoamerican
Council of Mar de La Plata [2005] issued a proposal rec-
ommending that the autologous use of the tissue be
restricted and that the creation of private, for-profit banks
be prohibited [21]. The Iberoamerican Council bases its
recommendation on the following facts: (i) the tissue
stored in private banks is seldom used; (ii) autologous use
assures complete compatibility, but there is no scientific
evidence that may justify the storage of tissue samples
indefinitely; (iii) the obligation of governments to prefer-
entially promote treatments of efficacy as proven scientif-
ically; (iv) the importance of taking into consideration the
results of a cost-benefit analysis.BMC Medical Ethics 2009, 10:12 http://www.biomedcentral.com/1472-6939/10/12
Page 3 of 8
(page number not for citation purposes)
The European Group on the Ethics of Science and New
Technologies states that the donation of human tissues
must be freely done, that it must be altruistic, and that the
donor does not have to receive remuneration. For this
group it is also important that the donation be based on
the notion of solidarity, and the donor not be considered
as an object that provides organs and tissues, but as a per-
son. And the group is emphatic on the need to avoid the
exploitation of the more disadvantaged social classes, the
class more likely to donate when the donations are not
altruistic [22]. Italy is the only country of the European
Union which expressly prohibits the existence of privately
owned, for-profit, BCUs because the allogenic use of stem
cells from the umbilical cord is still under investigation
[6].
The American Academy of Pediatrics through its Pediatric
BCU Group discourages parents from using private stor-
age facilities, despite the fact that they acknowledge the
possibility of future autologous use, above all, in illnesses
with genetically determined immune deficiency, and in
some other acquired diseases of the bone marrow. They
also believe that the parents are subjected to the undue
influence, coercion and manipulation by private banks in
order to obtain consent for the storage of blood at the
moment of birth, taking advantage of the emotions that
are displayed on such an occasion [15].
There are a number of ethical, legal and social problems
lurking behind the operation of these banks. This article
presents a meticulous review of the topics related to the
UCB, and analyzes the ethical, legal, health policy, medi-
cal and scientific considerations that allow their operation
in Mexico.
Discussion
Public policy and legal considerations
There is a close relation between law and public policy. In
this article "public policy" refers to a set of normative
guidelines which a governmental entity may demand to
be followed. These public policies may prescribe that indi-
Table 1: Some of the differences in the operation of Umbilical Cord Blood Banks in Mexico
Private banks Public banks
Assure compatibility in 100% of cases. Compatibility reaches up to 90%.
The possibility of use by other members of the family of the donor is 
mentioned. This is an affirmation which is part of their marketing strategy.
A bioarchive of Histoleukocytic antigen is available to increase the 
possibility of compatibility.
The availability of the unit is immediate; however samples are regularly 
stored in foreign banks.
Availability is not immediate. A bioarchive assures better compatibility.
Storage costs are paid by the donor. On the average an initial payment of 
800 USD is required as well as annual payments of 90 USD. Financial plans 
for 5, 10, 15 and even 20 years are available.
No cost to the donor; all costs are paid by the State. They promote 
solidarity through the altruistic donation of umbilical cords. Any person 
may obtain a sample for medical treatment without the need to pay.
No evidence that NOM-003-SSA2-1993 or quality certificate ISO 9001–
2000 are being complied with; and no evidence of affiliation to 
international groups that would certify the adherence to quality standards.
Operation complies with international quality controls (World Association 
of Bone Marrow Transplants, International Foundation Netcord, American 
Association of Blood Banks AABB, Norma Oficial Mexicana NOM-003-
SSA2-1993, Quality certifications ISO 9001–2000.
Despite the absence of certified quality control for the storage and 
transport of the samples, all umbilical cord samples are stored.
Strict quality controls for the selection of donors, the acquisition, storage, 
transport and cellular viability. Only samples that meet strict standards of 
quality and cellular viability are stored.
The acquisition of samples is usually completed by a third party; thereby 
the responsibility to complete this task in a prescribed manner is diluted. 
This also creates the possibility of clandestine payments to those who 
acquire the samples; this would bias the sample acquisition process in favor 
of the private banks.
Acquisition is completed by trained personnel.
Table 2: Indications for the transplant of haematopoietic stem 
cells
Allogenic Autologous
Congenital Diseases
Congenital combined immunodeficiency *
Fanconi's medular aplasia *
Talasemia major *
Sickle cell *
Blackfan-Diamond's erythroblastopenia *
Kostmann's neutropenia *
Juvenile Osteopetrosis *
Thesaurismosis *
Chronic Granulomatous Disease *
Acquired Neoplastic Diseases
Acute Leukemias *
Chronic Myeloid Lukemia *
Chronic Lymphocytic Leukemia *
Non-Hodkin Lymphoma *
Hodgkin Lymphoma *
Multiple Myeloma *
Histiocytosis *
Myelodysplastic Syndrome *
Solid Tumors *
Non-neoplastic acquired diseases
Severe Marrow Aplasia *
* No indication
Table adapted from: Asociación Mexicana de Medicina Transfusional, 
A.C., Agrupación Mexicana para el Estudio de la Hematología, A.C. 
Guía para el uso clínico de la sangre. México: Secretaría de Salud; 
2007.BMC Medical Ethics 2009, 10:12 http://www.biomedcentral.com/1472-6939/10/12
Page 4 of 8
(page number not for citation purposes)
viduals and organizations behave or not behave in a cer-
tain way.
What has been discussed above signals the need for the
definition of public policy and law to regulate all aspects
of the functioning of UCBs, in particular: (1) what kind of
installations and trained personnel must an entity have
before it bills itself as a UCB, (2) what kind of standards
must the operations of these installations and personnel
meet, (3) who will certify that the standards are being met
at any given time, (4) how will informed consent to store
the tissue be obtained, (5) who will pay for the indefinite
storage of the tissue, and (6) who and under what circum-
stances will that person have access to the tissue stored.
But, this raises the following questions: What kinds of
interests are involved in the operation of private banks?
How can the State intervene to fill the fundamental health
needs of a population? What is fair in the acquisition of
samples? What is fair in accessing the samples stored?
What kind of input toward policy definition should come
from the existing public and private UCBS when the crite-
ria that define good practice are defined?
Despite the fact that there are international entities that
publish guidelines for the operation of UCBs, the majority
of nations do not have a specific legal framework for the
operation of these banks, nor do they have the health reg-
ulations that are in agreement with technological devel-
opment [1,6]. In Mexico, the therapeutic use of human
blood is regulated by: (a) the General Health Law (1984)
that establishes the basis and modes for the provision of
health care and for basic and applied health research.
However, the law is general and does not define the man-
ner in which the UCBs will be regulated. (b) The official
Mexican norm (NOM-003-SSA2-1993) [23], which must
be observed throughout the nation by the public and the
private sectors, regulates the therapeutic uses of human
blood and its components. However, it does not consider
the utilization of stem cells derived from umbilical cord
blood. The norm is limited to defining the manner and
conditions under which the following should be carried
out: the allogenic disposal and selection of the donor, the
collection and safekeeping, handling, storage and control
of all blood units and their components. (c) The docu-
ment on the clinical use of blood that was published by
the Health Ministry jointly with the Mexican Association
of Transfusion Medicine, A.C., and the Mexican Group for
the Study of Haematology, A.C., This document defines,
in Chapter VIII, the guidelines to be followed in order to
maintain standards of quality during the acquisition, stor-
age and use of stem cells from the umbilical cord [16]. The
document does not recommend autologous donations
because of the probability of the appearance of cancer,
congenital autoimmune deficiency or genetic diseases
associated with this procedure as reported in the literature
[16]. Nevertheless, it does not prohibit the storage of sam-
ples from umbilical cord in private banks. In this respect
it must be remembered that "The fact that an act is mor-
ally acceptable does not mean that the law must permit
it." [37].
The absence of these guidelines from Mexican legislation
implies the need for a serious reflection on the moral
responsibility of the legislative branches of government
previous to the definition of public law. This reflection
must consider, at least the six aspects of UCBs that must
be regulated with particular emphasis on the following:
(a) The process of informed consent should be previ-
ous to the donation and storage of blood from the
umbilical cord. International organizations recom-
mend that the written permission for obtaining cord
blood should be obtained long before onset of active
labor, so that parents will be able to decide freely and
responsibly [24,25]. It is interesting to note that the
American Pediatrics Association and the American
College of Obstetrics and Gynecology doubt the valid-
ity of informed consent obtained by private banks.
They state that these banks coerce and manipulate par-
ents in order to obtain their consent. The banks lead
them to believe that the possible treatment of a future
disease is in their hands, and they offer the service as
some sort of "biological insurance." This is a situation
that may generate guilt in the parents involved when
they cannot buy their offspring a "hope for life"
[12,26-28].
(b) The fact that ownership of the cord stored in pri-
vate banks passes to the child (donor) once he/she has
come of age [29]. This gives rise ethical concerns about
what future use will be made of tissue that is not used;
what is the reason that justifies a lifetime autologous
storage.
(c) Confidentiality of donor information. In private
banks this is not strictly kept [30]. For example, in
Spain, the Health Ministry, which was initially
opposed to the creation of private banks, allowed it
upon being required to store the tissue of the first
daughter of the Prince of Asturias, the first in line to
inherit the Spanish crown. Information about the stor-
age of this tissue was in the public domain [31-34],
and as a consequence, the Spanish Government issued
a decree (2006) stating that "the stem cells of private
banks will be used publicly"; therefore, any ill person
who may need a transplant and for whom compatible
cells may be found in private banks will be able to use
them [35,36].
All of this does not necessarily imply that Mexican law
should prohibit the establishment and operation of pri-
vate banks, but it does evidence the need for the existenceBMC Medical Ethics 2009, 10:12 http://www.biomedcentral.com/1472-6939/10/12
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of laws, norms and regulations to govern their operation
and the operation of publicly funded banks. And for this,
it is important to state that the authors of this article
believe that there is a natural right to store blood from the
umbilical cord and that any positive law about the storage
and use of UCB must be based upon it; and through this
positive law the legislative branches of government must
to seek the good of order – the common good – of the
population through which the particular good repre-
sented by the stored blood will be available to individuals.
With this consideration there emerges the need consider
the notion justice, which is nothing else but the willing-
ness to give each what is due to him or her, that is, what
corresponds to each [37].
Ethics, morals and UCBs
The ethical reasoning process has as its objective to reach
clarity, systematic order and precision in the arguments
through which we make a decision about what is good for
populations and individuals [37]. Therefore, ethical anal-
ysis must be systematic, and comply with the very
demands that are defined by reason: (1) be attentive to all
of the data available, (2) be intelligent and understand the
data, (3) be rational and judge whether the understanding
is correct or not, or probably correct or incorrect, (4) be
responsible and decide on the basis of what has been cor-
rectly understood [38,39].
At present, ethical thinking is polarized between those
who hold that there is a set of principles which is common
to all human beings, independently of differences in reli-
gion, politics and culture; and those who hold that ethical
principles are elements of a culture and different cultures
have different principles. Those who belong to the first
group assert that it is in judgments and decisions made on
the bases of these common principles, and also based on
the ethical traditions of medicine that the principles of
beneficence, non-maleficence, autonomy and justice may
be discovered [37,38]. Those that belong to the second
group state that there are no universal principles in ethics,
that is, there are no ethical principles which are valid for
all peoples for all time [40]. These two opposite perspec-
tives are important when reflecting upon the need for leg-
islation to regulate the operation of UCBs. However, this
paper is written from the position that there are certain
ethical principles which are universal. These principles
prima facie are used as the framework of reference for the
analysis it presents. This article is written from a position
that states that these principles constitute the basis for the
solution of ethical dilemmas. And, when these principles
are combined with the idea of public health as an element
of the common good (and as long as they are not reduced
to algorithms or rules from which all correct answers to
moral problems may be derived) they can provide the eth-
ical standard that allows for the evaluation of the opera-
tion of UCBs and the roles of everyone who is involved in
their operation, including: the UCB themselves, and the
donors, physicians/researchers as well as the communities
where they operate.
Beneficence
The ethical obligation to benefit the patient, while expos-
ing him/her to the smallest possible risk, is the basis for
the use of haematopoietic stem cells from the blood of the
umbilical cord in specific diseases (Table 2). This principle
is ignored or nor appropriately understood by private
banks when, on the one hand, they offer a service based
on false promises, such as that of "biological insurance,"
for which there is no scientific evidence; on the other
hand, deceiving donors by assuring them that the tissue
will remain in storage and available to be used at any
moment of the life of their child. It is appropriate to
underline that given the amount of tissue stored, it would
be absolutely necessary to use allogenic donors if it were
necessary to transplant an adult or if a patient (at any age)
required of a second transplant [19,20]. As to the idea of
cellular expansion (using in vitro techniques) it must be
stated that this is something which is still being investi-
gated [20,41]
Non maleficence
The traditional moral obligation of Hippocratic medicine
is primum non nocere, to first do no harm. In private banks,
as opposed to public banks, it is not known if the criteria
for quality control are followed and no harm is done.
These banks have no rigorous control over such as: cellu-
lar viability, sample volume, method of acquisition, han-
dling and transportation [11,42,43]. How then, could the
quality of the tissue transplanted be guaranteed when the
donor needs to use it?
Private banks should absorb their own quality control
costs as any other commercial enterprise. The Govern-
ment's job is to create health policies and regulations that
guarantee the ethical functioning of both types of UCBs
[44].
Autonomy
When the State guarantees the right of persons to choose
freely, it shows that the autonomy – self rule – of humans
is acknowledged by it and respected. The basis for
informed consent resides on the idea that competent per-
sons are by nature autonomous and the best guardians of
their own welfare. Public banks, in contrast to what hap-
pens in private banks, allow donors to exercise freely and
responsibly the right to choose to store the tissue, when
conflicts of interest are absent, due to the altruistic nature
of the donation.BMC Medical Ethics 2009, 10:12 http://www.biomedcentral.com/1472-6939/10/12
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With this in mind, then why would parents choose to
store blood from the umbilical cord of their child in a pri-
vate bank instead of doing in it a public bank? A number
of ethical question emerge immediately around this ques-
tion: can you speak of respect for autonomy – freedom of
choice – when, in private banks, consent is given under
pressure and under the weight of the uncertainty that sur-
rounds the possibility of suffering some disease in a dis-
tant future? When the person has been made false
promises about her health? It is evident that such forms of
coercion do not destroy the capacity to choose freely, but
they do weaken its rational foundation and the effective
range of its operation. And this is precisely what puts at
risk the acceptability of the informed consent to store
blood that is provided to private banks. This was evident
during the early history of the public UCB of the "La Raza"
National Medical Center of the Mexican Social Security
Institute. It began its operation by acquiring umbilical
cord samples in the "Santa Helena" private hospital. The
strategy for acquiring the samples consisted in the promo-
tion of the donation of the umbilical cord to the bank of
the private hospital and for the public bank, simultane-
ously. Parents were informed of the advantages and disad-
vantages of both banks, without creating any false
expectation about the possible use of the tissue. It was
observed that when there is no coercion of any type par-
ents prefer altruistic donation [Novello-Garza B.; Unpub-
lished observations].
One corollary of autonomy is the principle of Respect for
Persons. And Respect for persons requires that confidenti-
ality and honesty (not to deceive or lie) be kept. In public
banks the acquisition of samples is governed by the prin-
ciples of altruism, autonomy, respect for person and con-
fidentiality. Since private banks do not assure
confidentiality and put at risk the reason for storing the
umbilical cord – autologous use – they face a significant
dilemma when confronted with these principles.
Justice
Using the Mexican Constitution, which establishes that
every Mexican citizen has a right to the protection of his/
her health through access to the national and state health
systems that guarantee it [Article 4] [45], it is logical to ask
the following: Is it a duty of the Mexican government to
encourage the establishment of the UCBs, and to analyze
the advantages and disadvantages of public and private
banks in order to determine the type of UCB that could
provide the maximum benefit to the majority of the pop-
ulation, including its most disadvantaged sectors? Public
banks through a bioarchive offer the availability of HLA
compatibles for allogenic transplants, and have the possi-
bility of extending their operation to benefit the many
ethnicities that weave the fabric of Mexican society,
because they are embedded in national health care sys-
tems, and networks that sometimes are international in
nature. Samples stored in private banks, as has already
been mentioned, can only be used for the donor and with
the caveats that have been identified by scientific research
[6,15,17-20]. But, what can be said of the mercantile atti-
tude of private banks (in relation to the storage of biolog-
ical materials) when this has no scientific justification?
And, since these private banks serve a population well
resourced and with a range of options that people with
less resources have, from a moral perspective it seems that
they should never be subsidized by the government, be it
federal, state or local. Clinical Ethics Committees (CEC)
play here a fundamental role by creating the instances in
which reflection and deliberation may occur about the
services, the way they are funded, and consequences of the
operation of the UCBs. Policy and guideline development
is seen as an important function by many CEC [46].
The notion of justice also is called into question when the
distribution of the operating Mexican banks is taken into
consideration. Public UCBs are located in large metropol-
itan areas: Mexico City (n = 2) and Nuevo León (n = 1);
hence, they are not accessible to most of the Mexican pop-
ulation. The only bank that has attempted to be accessible
and serve a more inclusive population is the Central
Blood Bank at the "La Raza" National Centre. This centre
is projecting to work with teams of health professionals so
that they turn out at specific geographical areas in order to
constitute a more complete bioarchive. It is also impor-
tant to mention that umbilical cord units are granted to
any patient by the public transplant centres which are
located in Mexico City, Monterrey, Puebla and Guadala-
jara.
Conclusion
To reflect on the UCBs' work within the field of public
health policy and ethics is an opportunity to show the
need for creating, developing, and modifying all those
health policies that aim at reconciling goals such as
informed consent, equal access to health care, health pro-
motion and social efficiency. Inequalities in access to the
banks and health care, combined with high cost of tissue
storage and high recovery fees of CB units granted for
transplant, give rise debates about basic medical ethics
and social justice in many countries, including Mexico.
Summary
The storage of blood from the UCBs in order to harvest
hematopoietic stem cells to deal with genetic, congenital
and acquired diseases appeared about 30 years ago and is
coming into its own. In Mexico there are public and pri-
vately funded UCBs. However, present Mexican law is
general and lacks the specificity necessary for the regula-
tion of the UCBs. Although there are international recom-
mendations for the control of these banks, there are
certain legal and ethical aspects which are omitted from
consideration. Ethical analysis allows for the evaluation ofBMC Medical Ethics 2009, 10:12 http://www.biomedcentral.com/1472-6939/10/12
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the Mexican legislation and finds the need for specific leg-
islation to regulate the UCBs. This article is important
because along with establishing the need that the Mexican
State regulate and supervise, in a strict manner, the opera-
tion of both types of UCB, it shows that it is of extreme
importance to bring up to date the General Health Law
and the Mexican Official Norm (Ley General de Salud y la
Norma Oficial Mexicana) for the appropriate use of
human blood and blood derivatives in medical treat-
ments and clinical research. The new legislation and the
updating of the legislation already in place will forestall
the continuation all inappropriate use of haematopoietic
stem cell; and will also regulate the advertising campaigns
and marketing of private banks. The new legislation
should call for periodic audits of the UCBs in order to
assess and very the quality of their operation.
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